Chinese General Practice ›› 2023, Vol. 26 ›› Issue (26): 3246-3251.DOI: 10.12114/j.issn.1007-9572.2023.0183
• Original Research·Monographic Research·Type 2 Diabetic • Previous Articles Next Articles
Received:
2023-03-20
Revised:
2023-04-26
Published:
2023-09-15
Online:
2023-05-20
Contact:
ZHANG Qiang
通讯作者:
张强
作者简介:
基金资助:
项目 | 非AF组(n=283) | AF组(n=34) | 检验统计量值 | P值 |
---|---|---|---|---|
年龄( | 70.3±12.6 | 76.1±9.4 | 6.649a | 0.010 |
性别〔例(%)〕 | 0.064b | 0.800 | ||
女 | 148(52.3) | 17(50.0) | ||
男 | 135(47.7) | 17(50.0) | ||
BMI( | 25.4±3.0 | 24.8±4.4 | 1.061a | 0.304 |
SBP〔M(P25,P75),mmHg〕 | 136(127,156) | 142(133,152) | 2.836 | 0.092 |
DBP〔M(P25,P75),mmHg〕 | 76(70,83) | 78(70,89) | 1.792 | 0.181 |
血生化指标 | ||||
HbA1c平均值( | 7.41±1.30 | 7.35±1.55 | 0.467a | 0.494 |
HbA1c-SD( | 0.34±0.04 | 0.38±0.03 | 29.694a | <0.001 |
HbA1c-CV( | 4.70±0.90 | 5.35±1.13 | 15.312a | <0.001 |
NT-proBNP〔M(P25,P75),ng/L〕 | 303.0(166.0,668.7) | 485.0(262.5,737.5) | 2.507 | 0.113 |
Cr〔M(P25,P75),μmol/L〕 | 73.0(58.0,103.0) | 83.0(62.0,96.0) | 0.988 | 0.320 |
Ccr〔M(P25,P75),mL·min-1·(1.73 m2)-1〕 | 72.8(54.1,99.8) | 62.1(46.1,81.5) | 4.628 | 0.031 |
UA〔M(P25,P75),μmol/L〕 | 327.0(273.5,391.0) | 339.0(274.0,452.0) | 1.750 | 0.186 |
LDL-C〔M(P25,P75),mmol/L〕 | 2.2(1.6,3.2) | 2.1(1.4,2.8) | 1.682 | 0.195 |
HDL-C〔M(P25,P75),mmol/L〕 | 1.1(0.9,1.3) | 1.2(1.0,1.4) | 3.422 | 0.064 |
TG〔M(P25,P75),mmol/L〕 | 1.4(1.0,1.9) | 1.1(0.9,1.6) | 5.470 | 0.019 |
TC〔M(P25,P75),mmol/L〕 | 3.9(3.1,4.8) | 3.6(2.7,4.5) | 1.305 | 0.253 |
超声指标 | ||||
LVEF〔M(P25,P75),%〕 | 60.0(57.0,61.0) | 57.5(53.5,60.0) | 7.301 | 0.007 |
LAD〔M(P25,P75),mm〕 | 37.0(33.0,40.0) | 42.0(38.0,46.0) | 21.704 | <0.001 |
LVDD〔M(P25,P75),mm〕 | 45.0(42.0,49.0) | 44.5(43.0,47.0) | 0.498 | 0.480 |
IVST〔M(P25,P75),mm〕 | 12.0(10.0,13.0) | 11.0(10.0,12.0) | 2.165 | 0.141 |
LVPW〔M(P25,P75),mm〕 | 10.0(10.0,11.0) | 10.0(10.0,11.0) | 0.059 | 0.809 |
LVMI〔M(P25,P75),g/m2〕 | 118.0(98.8,135.6) | 112.9(100.6,128.4) | 0.769 | 0.381 |
用药情况〔例(%)〕 | ||||
β受体阻滞剂 | 190(67.1) | 27(79.4) | 2.118b | 0.146 |
钙通道拮抗剂 | 145(51.2) | 6(17.6) | 13.729b | <0.001 |
ACEI/ARB | 176(62.2) | 16(47.1) | 2.910b | 0.088 |
利尿剂 | 53(18.7) | 18(52.9) | 20.442b | <0.001 |
醛固酮受体拮抗剂 | 40(14.1) | 17(50.0) | 26.475b | <0.001 |
他汀类降脂药 | 244(86.2) | 27(79.4) | — | 0.303 |
心功能分级〔例(%)〕 | — | <0.001 | ||
Ⅰ~Ⅱ级 | 270(95.4) | 23(67.6) | ||
Ⅲ~Ⅳ级 | 13(4.6) | 11(32.4) |
Table 1 Comparison of baseline characteristics of patients in the two groups
项目 | 非AF组(n=283) | AF组(n=34) | 检验统计量值 | P值 |
---|---|---|---|---|
年龄( | 70.3±12.6 | 76.1±9.4 | 6.649a | 0.010 |
性别〔例(%)〕 | 0.064b | 0.800 | ||
女 | 148(52.3) | 17(50.0) | ||
男 | 135(47.7) | 17(50.0) | ||
BMI( | 25.4±3.0 | 24.8±4.4 | 1.061a | 0.304 |
SBP〔M(P25,P75),mmHg〕 | 136(127,156) | 142(133,152) | 2.836 | 0.092 |
DBP〔M(P25,P75),mmHg〕 | 76(70,83) | 78(70,89) | 1.792 | 0.181 |
血生化指标 | ||||
HbA1c平均值( | 7.41±1.30 | 7.35±1.55 | 0.467a | 0.494 |
HbA1c-SD( | 0.34±0.04 | 0.38±0.03 | 29.694a | <0.001 |
HbA1c-CV( | 4.70±0.90 | 5.35±1.13 | 15.312a | <0.001 |
NT-proBNP〔M(P25,P75),ng/L〕 | 303.0(166.0,668.7) | 485.0(262.5,737.5) | 2.507 | 0.113 |
Cr〔M(P25,P75),μmol/L〕 | 73.0(58.0,103.0) | 83.0(62.0,96.0) | 0.988 | 0.320 |
Ccr〔M(P25,P75),mL·min-1·(1.73 m2)-1〕 | 72.8(54.1,99.8) | 62.1(46.1,81.5) | 4.628 | 0.031 |
UA〔M(P25,P75),μmol/L〕 | 327.0(273.5,391.0) | 339.0(274.0,452.0) | 1.750 | 0.186 |
LDL-C〔M(P25,P75),mmol/L〕 | 2.2(1.6,3.2) | 2.1(1.4,2.8) | 1.682 | 0.195 |
HDL-C〔M(P25,P75),mmol/L〕 | 1.1(0.9,1.3) | 1.2(1.0,1.4) | 3.422 | 0.064 |
TG〔M(P25,P75),mmol/L〕 | 1.4(1.0,1.9) | 1.1(0.9,1.6) | 5.470 | 0.019 |
TC〔M(P25,P75),mmol/L〕 | 3.9(3.1,4.8) | 3.6(2.7,4.5) | 1.305 | 0.253 |
超声指标 | ||||
LVEF〔M(P25,P75),%〕 | 60.0(57.0,61.0) | 57.5(53.5,60.0) | 7.301 | 0.007 |
LAD〔M(P25,P75),mm〕 | 37.0(33.0,40.0) | 42.0(38.0,46.0) | 21.704 | <0.001 |
LVDD〔M(P25,P75),mm〕 | 45.0(42.0,49.0) | 44.5(43.0,47.0) | 0.498 | 0.480 |
IVST〔M(P25,P75),mm〕 | 12.0(10.0,13.0) | 11.0(10.0,12.0) | 2.165 | 0.141 |
LVPW〔M(P25,P75),mm〕 | 10.0(10.0,11.0) | 10.0(10.0,11.0) | 0.059 | 0.809 |
LVMI〔M(P25,P75),g/m2〕 | 118.0(98.8,135.6) | 112.9(100.6,128.4) | 0.769 | 0.381 |
用药情况〔例(%)〕 | ||||
β受体阻滞剂 | 190(67.1) | 27(79.4) | 2.118b | 0.146 |
钙通道拮抗剂 | 145(51.2) | 6(17.6) | 13.729b | <0.001 |
ACEI/ARB | 176(62.2) | 16(47.1) | 2.910b | 0.088 |
利尿剂 | 53(18.7) | 18(52.9) | 20.442b | <0.001 |
醛固酮受体拮抗剂 | 40(14.1) | 17(50.0) | 26.475b | <0.001 |
他汀类降脂药 | 244(86.2) | 27(79.4) | — | 0.303 |
心功能分级〔例(%)〕 | — | <0.001 | ||
Ⅰ~Ⅱ级 | 270(95.4) | 23(67.6) | ||
Ⅲ~Ⅳ级 | 13(4.6) | 11(32.4) |
影响因素 | B | SE | Wald χ2值 | P值 | HR(95%CI) |
---|---|---|---|---|---|
HbA1c-SD | 0.767 | 0.177 | 18.669 | <0.001 | 2.15(1.52,3.05) |
HbA1c-CV | 0.392 | 0.167 | 5.497 | 0.019 | 1.48(1.07,2.06) |
年龄 | 0.037 | 0.017 | 5.011 | 0.025 | 1.04(1.01,1.07) |
Ccr | -0.011 | 0.006 | 3.789 | 0.051 | 0.99(0.98,1.00) |
UA | 0.004 | 0.002 | 4.644 | 0.031 | 1.00(1.00,1.01) |
TG | -0.680 | 0.290 | 5.500 | 0.019 | 0.51(0.29,0.89) |
LVEF | -0.164 | 0.047 | 9.457 | 0.002 | 0.87(0.79,0.95) |
LAD | 0.141 | 0.038 | 13.769 | <0.001 | 1.15(1.07,1.24) |
钙通道拮抗剂 | -1.543 | 0.451 | 11.727 | 0.001 | 0.21(0.09,0.52) |
ACEI/ARB | -0.731 | 0.349 | 4.394 | 0.036 | 0.48(0.24,0.95) |
利尿剂 | 1.490 | 0.344 | 18.719 | <0.001 | 4.44(2.26,8.71) |
醛固酮受体拮抗剂 | 1.561 | 0.344 | 20.614 | <0.001 | 4.76(2.43,9.35) |
心功能分级 | 2.074 | 0.374 | 30.815 | <0.001 | 7.96(3.83,16.55) |
Table 2 Univariate Cox regression analysis of new-onset AF in T2DM patients combined with HFpEF
影响因素 | B | SE | Wald χ2值 | P值 | HR(95%CI) |
---|---|---|---|---|---|
HbA1c-SD | 0.767 | 0.177 | 18.669 | <0.001 | 2.15(1.52,3.05) |
HbA1c-CV | 0.392 | 0.167 | 5.497 | 0.019 | 1.48(1.07,2.06) |
年龄 | 0.037 | 0.017 | 5.011 | 0.025 | 1.04(1.01,1.07) |
Ccr | -0.011 | 0.006 | 3.789 | 0.051 | 0.99(0.98,1.00) |
UA | 0.004 | 0.002 | 4.644 | 0.031 | 1.00(1.00,1.01) |
TG | -0.680 | 0.290 | 5.500 | 0.019 | 0.51(0.29,0.89) |
LVEF | -0.164 | 0.047 | 9.457 | 0.002 | 0.87(0.79,0.95) |
LAD | 0.141 | 0.038 | 13.769 | <0.001 | 1.15(1.07,1.24) |
钙通道拮抗剂 | -1.543 | 0.451 | 11.727 | 0.001 | 0.21(0.09,0.52) |
ACEI/ARB | -0.731 | 0.349 | 4.394 | 0.036 | 0.48(0.24,0.95) |
利尿剂 | 1.490 | 0.344 | 18.719 | <0.001 | 4.44(2.26,8.71) |
醛固酮受体拮抗剂 | 1.561 | 0.344 | 20.614 | <0.001 | 4.76(2.43,9.35) |
心功能分级 | 2.074 | 0.374 | 30.815 | <0.001 | 7.96(3.83,16.55) |
[1] | |
[2] |
|
[3] |
|
[4] |
包丽雯. 射血分数保留心力衰竭与2型糖尿病的研究进展[J]. 复旦学报(医学版),2020,47(5):789-794. DOI:10.3969/j.issn.1672-8467.2020.05.023.
|
[5] |
黄从新,张澍,黄德嘉,等. 心房颤动:目前的认识和治疗的建议—2018[J]. 中国心脏起搏与心电生理杂志,2018,32(4):315-368.
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
中华医学会内分泌学分会. 糖尿病患者血糖波动管理专家共识[J]. 中华内分泌代谢杂志,2017,33(8):633-636. DOI:10.3760/cma.j.issn.1000-6699.2017.08.002
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[25] |
|
[1] | ZHANG Aili, HOU Qiqi, HAN Quanle, ZHANG Boheng, ZHANG Jiawei, CAO Hongxia, ZHANG Chao, CHEN Shuohua, WU Shouling, LI Kangbo. Correlation between Atrial Fibrillation and the Risk of New-onset Chronic Kidney Disease in Northern Chinese Population [J]. Chinese General Practice, 2023, 26(36): 4521-4526. |
[2] | LIU Puqing, CHEN Jingwen, SHOU Zhangxuan. Evaluation of Potentially Inappropriate Medication of Direct Oral Anticoagulant in Hospitalized Elderly Patients with Non-valvular Atrial Fibrillation Based on Beers Criteria [J]. Chinese General Practice, 2023, 26(35): 4388-4393. |
[3] | ZHANG Jin, DING Zhiguo, QI Shuo, LI Ying, LI Weiqiang, ZHANG Yuanyuan, ZHOU Tong. Relationship between Serum Thyroid Hormone Levels and Prognosis during Hospitalization in Heart Failure Patients [J]. Chinese General Practice, 2023, 26(33): 4125-4129. |
[4] | MA Yanyan, REN Fuxian, WANG Yu, GAO Dengfeng. The Prediction Value of (Neutrophil+Monocyte) /Lymphocyte Ratio on In-hospital Mortality of Heart Failure Patients [J]. Chinese General Practice, 2023, 26(30): 3791-3796. |
[5] | ZHANG Zhendong, CAI Bin, WANG Hongwei, QIAO Zengyong. Study on the Changes of Intestinal Flora and Its Metabolite Phenylacetylglutamine in Patients with Chronic Heart Failure [J]. Chinese General Practice, 2023, 26(29): 3665-3673. |
[6] | XU Di, TIAN Jinping, LIU Yunyue, XUE Leng, ZHANG Lin, SUN Guozhen, WANG Liansheng, XU Jingjing. Characteristics and Influencing Factors of Glycemic Fluctuation in Patients with Coronary Heart Disease with Type 2 Diabetes during the Peri-PCI Period [J]. Chinese General Practice, 2023, 26(15): 1863-1872. |
[7] | YUE Bocheng, HOU Qiqi, HAN Quanle, YANG Bo, WU Zheng, WU Jianmei, CHEN Shuohua, WU Shouling, LI Kangbo. Effect of Atrial Fibrillation on the Risk of New-onset Myocardial Infarction in Hypertensive Population [J]. Chinese General Practice, 2023, 26(14): 1739-1744. |
[8] | CHEN Ruimin, LIU Fang, TAN Hong, HAN Shufang, CHEN Yingjian, SU Congcong. Effects of Dapagliflozin on the Expression of MicroRNA-423-5p and Cardiac Function in Patients with Type 2 Diabetes Mellitus and Chronic Heart Failure [J]. Chinese General Practice, 2023, 26(14): 1733-1738. |
[9] | GAO Ying, JIN Yujing, WEI Wei, XU Xiaoqian, LI Shu, YANG Hongxi, ZHANG Qing. Association between Chronic Disease Risk Score and Cancer Risk: a Cohort Study [J]. Chinese General Practice, 2023, 26(12): 1429-1436. |
[10] | YANG Yi, CONG Huiwen, WANG Lianyuan, YANG Liping, BAO Qihan, WANG Haohua, LI Chengsheng, ZHOU Liwen, DING Zichen, SHI Fuyan, WANG Suzhen. Longitudinal Study on the Risk Factors of Stroke in Check-up Population Based on Bayesian Multivariate Joint Model [J]. Chinese General Practice, 2023, 26(12): 1437-1443. |
[11] | ZHANG Ning, HOU Ming, MEI Bo, JIN Weitao, TAN Xiong, YANG Mingchuan, WANG Liang, LIU Yong, LAI Yinglong. Hybrid Ablation: a Future Development Trend in the Management of Atrial Fibrillation [J]. Chinese General Practice, 2023, 26(09): 1136-1145. |
[12] | RUAN Haiyan, LI Liying, ZHANG Muxin, ZHENG Yi, HE Sen. Establishment of a Risk Prediction Model for Thrombotic Events in Chinese Patients with Hypertrophic Cardiomyopathy [J]. Chinese General Practice, 2023, 26(08): 917-926. |
[13] | DUAN Yuanxia, GU Liuna, ZHANG Lei, ZHOU Liting, ZHU Haiying, YANG Chao, CHEN Haiying, GU Xiaoqing, HUANG Jiaoling, GU Jie. Analyze Mastery of Atrial Fibrillation Related Knowledge and Its Influencing Factors among Grassroots Medical Staffs [J]. Chinese General Practice, 2023, 26(07): 869-876. |
[14] | HU Huachao, CHEN Xianya, XIE Siyuan, XIA Zhen, XIAO Hua. Clinical Characteristics and Treatment of Atrial Fibrillation and Heart Failure: a Multicenter Survey [J]. Chinese General Practice, 2023, 26(05): 541-549. |
[15] | CHEN Ying, ZHENG Hui, HE Yu. Association between Nutritional Status and Prognosis in Elderly Patients with Heart Failure with Preserved Ejection Fraction and Coronary Heart Diseases [J]. Chinese General Practice, 2023, 26(03): 335-342. |
Viewed | ||||||||||||||||||||||||||||||||||||||||||||||||||
Full text 353
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Abstract 503
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||